
Medexus Pharmaceuticals Inc
TSX:MDP

Gross Margin
Medexus Pharmaceuticals Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
CA |
![]() |
Medexus Pharmaceuticals Inc
TSX:MDP
|
92.6m CAD |
53%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
659.7B USD |
83%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
429.6B USD |
68%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.7B CHF |
74%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
84%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
185.6B GBP |
82%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
196.3B CHF |
76%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
214.8B USD |
78%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
68%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
143.5B USD |
74%
|
Medexus Pharmaceuticals Inc
Glance View
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.

See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Medexus Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 52.6%.